ReviewClinical rheumatology2009
Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases.
Review in Clinical rheumatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The topic of drug safety has received great attention in recent years. Pharmacoepidemiology is the study of the use and effects of medicines in large populations using epidemiological methods. Pharmacoepidemiologic research can fill the knowledge gaps due to the limitations of existing pharmacovigilance systems that rely on randomised controlled trials and voluntary reporting. This review discusses the present state of pharmacoepidemiologic research in Australia. In Australia, linking administrative data on use of medications and medical services is possible to a certain extent. Data from patient registries with respect to rheumatology are also available. These data are valuable for better understanding of the beneficial and adverse effects of medicines. Opportunities and challenges of using these data sources to address issues from clinical pharmacology are also highlighted. Australia is well-placed internationally to make major contributions to the knowledge base of outcomes of medicines in the real-world setting. Developments in pharmacoepidemiology are critical to clinicians treating patients with rheumatic and other conditions.
Indexed as
Identifiers
19190976What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.